Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

3.930 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 3 4 5 Next >

Zura Bio to Participate in the Cantor Global Healthcare Conference

August 31, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026

From Zura Bio Limited

Via Business Wire

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗

July 08, 2026

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.

Via Benzinga

ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗

May 07, 2026

Via Chartmill

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

May 13, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 07, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 04, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

March 19, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

March 05, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Participate in Upcoming Investor Conferences

March 02, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 27, 2026

From Zura Bio Limited

Via Business Wire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

February 25, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

February 24, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

February 23, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

February 04, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

January 21, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Business Updates and Outlook for 2026

January 12, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

November 13, 2025

From Zura Bio Limited

Via Business Wire

Unusual volume stocks are being observed in Wednesday's session. ↗

October 01, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

Here are the top movers in Tuesday's session. ↗

September 30, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

These stocks are moving in today's session ↗

September 30, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

Top stock movements in today's session. ↗

September 29, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.